spacer
home > ict > spring 2021 > the resilience of real-world data
PUBLICATIONS
International Clinical Trials

The Resilience of Real-World Data



Real-world data (RWD), or patient data derived from sources outside of traditional clinical trials, are increasingly being used to drive innovation across the healthcare industry. The expanded use and value of RWD spans across the trial lifecycle and the broader healthcare industry. The impact of this data is being seen in everything from clinical development, regulatory decision-making, pricing, and access to healthcare – and regulators are supportive. Following the 21st Century Cures Act, which placed additional focus on the use of these types of data to support regulatory decisions, the FDA has published extensive guidance to support and encourage the use of RWD in clinical research, and many other regulatory bodies around the world have followed.

Most significantly, RWD is being used to support trial design to both predict clinical response and select appropriate outcome measures. In clinical trial recruitment, it can help identify eligible patient populations more quickly, leading to more cost-effective trials and new therapies being brought to market faster.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Paul O’Donohoe is Scientific Lead, eCOA and Mobile Health at Medidata, a clinical software platform provider and a Dassault Systèmes company. He is responsible for developing the company’s scientific expertise for eCOAs and mobile health, and is responsible for ensuring internal teams, partners, and sponsors are following industry, regulatory, and scientific best practices when it comes to integrating technology into clinical trials. He is passionate about developing the field of eCOA and mobile health through research and active involvement in industry consortia, and is currently the Industry Vice-Director of the C-Path ePRO Consortium. Prior to Medidata, Paul was Director of Health Outcomes at CRF Health, an eCOA provider.
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement